Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood ...
Haemonetics Corporation, founded in 1971 and headquartered in Boston, Massachusetts, is a global healthcare enterprise that develops and markets medical products and solutions across three primary business segments: Plasma, Blood Center, and Hospital. The Plasma segment focuses on automated plasma collection systems, such as the NexSys PCS and PCS2 devices, ...Haemonetics Corporation, founded in 1971 and headquartered in Boston, Massachusetts, is a global healthcare enterprise that develops and markets medical products and solutions across three primary business segments: Plasma, Blood Center, and Hospital. The Plasma segment focuses on automated plasma collection systems, such as the NexSys PCS and PCS2 devices, along with disposables and intravenous solutions, and offers integrated information technology platforms like NexLynk DMS to help plasma centers manage donors and operations efficiently. The Blood Center division provides advanced automated blood component collection technology, including MCS apheresis equipment and disposable kits, as well as software like SafeTrace Tx and BloodTrack to enhance blood bank operations and bedside transfusions. For the Hospital segment, Haemonetics offers hemostasis analyzers (TEG, ClotPro, HAS) that assess clotting ability, and the Cell Saver Elite+ system for autologous blood recovery in various surgical procedures. The company distributes its products through direct sales teams, distributors, and sales representatives. With approximately 3,009 employees, Haemonetics reported a market capitalization of about $3.99 billion, a price-to-earnings ratio of 42.6, and a gross profit margin of 57.4%. The company's financial metrics show a solid operational performance with an operating margin of 18.2% and a net margin of 7.1%, despite a significant debt load (debt-to-equity ratio of 1.4). Under the leadership of CEO Christopher Simon, who has over 30 years of experience, Haemonetics continues to innovate in blood management and medical technology, aiming to improve patient care and operational efficiency for healthcare providers worldwide. The company's commitment to advancing healthcare is reflected in its continuous R&D investments (4.4% of revenue) and its focus on delivering high-quality solutions that address critical needs in plasma collection, blood banking, and surgical care.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$1.3B
-2.0%
-2.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$97.3M
-42.0%
+263.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+55.7%
-2.6%
+4.4%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
+18.1%
+11.0%
+14.0%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
+7.3%
-40.8%
+267.2%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$260.4M
+82.8%
-16.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
+19.5%
+86.5%
-14.9%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
153.8%
+3.1%
-8.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.95x
+82.7%
+4.3%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Good day, and thank you for standing by. Welcome to the Haemonetics Corporation First Quarter 2027 Earnings Conference Call. [Operator Instructions]. Please be advised today's conference is being recorded. I would now like to hand the conference over to your speaker today, Olga Guyette, Vice President, Investor Relations and Treasurer. Please go ahead.
Olga Guyette: Good morning, and thank you for joining us for Haemonetics first quarter fiscal year 2027 conference call and webcast. I'm joined today by Chris Simon, our CEO; and James D'Arecca, our CFO. This morning, we reported first quarter fiscal '27 results and raised our fiscal 2027 guidance. Our earnings release, supplemental presentation and related materials are available in the Investor Relations section of our website. First quarter results are reported under the new reportable segment structure announced on June 5, 2026. Additional information, including historical recast financials and the presentation describing the changes is also available on our Investor Relations website. Before we begin, I'd like to remind everyone that we will use both reported and organic revenue growth rates that exclude the impact of FX and the exit of liquid solutions, and our fiscal year 2027 guidance is also adjusted for the impact of the 53rd week. We'll refer to other non-GAAP financial measures to help investors understand Haemonetics' ongoing business performance. Please note that these measures exclude certain charges and income items. A full list of excluded items, reconciliations to our GAAP results and comparisons with the prior year periods are provided in our earnings release. Our remarks today include forward-looking statements, and our actual results may differ materially from the anticipated results. Factors that may cause our results to differ include those referenced in the safe harbor statement in today's earnings release and in other SEC filings. We do not undertake any obligation to update these forward-looking statements. And with that, I'd like to turn the call over to Chris.
Christopher Simon: Good morning, everyone. Thank you for joining. We started FY '27 strong with broad-based execution driving another quarter of profitable growth. First quarter revenue was $339 million, increasing 6% reported and organic, while adjusted earnings per diluted share increased 4% to $1.14. Investments we have made to enhance our portfolio, improve our operating model and strengthen commercial execution, are fueling consistent growth and strong cash generation. All three of our core platforms contributed to our performance this quarter, demonstrating the breadth of our business and reinforcing the confidence in our ability to deliver sustainable long-term growth. Before discussing our business results, I'd like to welcome Dr. Martin Madaus to our Board of Directors. Martin has built a distinguished career leading global health care businesses through transformation, strengthening execution …
